Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The hematocrit test devices market has experienced notable growth recently, driven by increasing healthcare needs and advancements in diagnostic technologies. As conditions related to blood health become more prevalent, the demand for accurate and efficient hematocrit testing solutions is rising. This overview explores the market’s current size, growth factors, key players, and evolving innovations shaping its future.

Current Market Size and Projected Growth of the Hematocrit Test Devices Market

The hematocrit test devices market demonstrated strong expansion from $4.91 billion in 2025 to $5.22 billion in 2026, growing at a compound annual growth rate (CAGR) of 6.4%. This growth during the past years has been driven by a rise in anemia and blood disorder cases, increasing diagnostic testing in hospitals and laboratories, higher demand for screening blood donors, the broadening scope of emergency and trauma care, and a stronger awareness of hematocrit monitoring in clinical settings. Looking ahead, the market is forecasted to reach $6.47 billion by 2030, growing at a CAGR of 5.5%. This anticipated growth will be fueled by the expanding need for point-of-care diagnostics, the rising incidence of chronic and lifestyle-related illnesses, the growth of decentralized health services and home-testing options, increased investments in diagnostic infrastructure, and a growing emphasis on early disease detection and preventive healthcare.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15582&type=smp

Factors Supporting Demand Growth in the Hematocrit Test Devices Market

One key element bolstering the hematocrit test devices market is the rising occurrence of blood disorders worldwide. These disorders impact various blood components such as red and white blood cells, platelets, and plasma. Their increasing prevalence is influenced by genetic factors, environmental pollution, and lifestyle changes. Hematocrit test devices play a vital role in measuring the proportion of red blood cells in blood, providing essential data on a patient’s hematologic status. For instance, the American Cancer Society’s January 2024 report expects about 62,770 new leukemia cases in the US in 2024, with approximately 23,670 deaths. Acute myeloid leukemia (AML) accounts for roughly 20,800 new cases, primarily in adults, and about 11,220 deaths mostly within this group. Such statistics highlight how the rising number of blood disorders is steering demand for hematocrit testing technologies.

Additional Drivers Accelerating Hematocrit Test Devices Market Demand

Moreover, the growing awareness of hematocrit testing’s importance in routine health monitoring and chronic disease management continues to propel the market. The expansion of healthcare infrastructure and the integration of advanced diagnostic tools contribute further. Emergency care settings increasingly rely on rapid hematocrit testing to guide treatment decisions, enhancing patient outcomes and efficiency.

Access The Complete Hematocrit Test Devices Market Report:

https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report

Hematocrit Test Devices Market Segmentation and Revenue Generators

The hematocrit test devices market is categorized into several segments to better understand its scope:

1) Product types: Hematocrit Test Meter, Hematocrit Test Analyzer, and Reagents and Consumables.

2) Applications: Anemia, Polycythemia Vera, Congenital Heart Diseases, and other uses.

3) End-Users: Hospitals and Ambulatory Surgical Centers, Clinics, Diagnostic and Pathology Labs, and various other end-users.

Within product subcategories, hematocrit test meters include handheld, portable, desktop, point-of-care, digital, and battery-powered variants. Hematocrit analyzers range from automated, benchtop, semi-automated, microhematocrit, high-throughput, to compact analyzers. Reagents and consumables consist of test strips, pipettes and capillaries, blood collection tubes, quality control reagents, calibration standards, and disposable kits.

Technological Developments and Innovations Driving Market Transformation

Leading companies in the hematocrit test devices sector are advancing their offerings by focusing on user-friendly platforms suited for medium-volume laboratories. These systems emphasize ease of use with minimal training required. For example, in March 2024, Mindray introduced the BC-700 Series, a compact hematology analyzer combining CBC and ESR testing in one device designed for smaller labs. It delivers results in 1.5 minutes, improving workflow efficiency. Its SF Cube 3D analysis technology allows precise cell differentiation, and the inclusion of the PLT-H parameter enhances platelet counting. Combining multiple tests into a single unit reduces costs for equipment and consumables. Available in open vial and autoloader formats, the BC-700 Series offers reliable, automated, and space-saving testing with strong consistency compared to traditional methods, alongside improved safety and repeatability.

Key Companies Leading the Hematocrit Test Devices Market Competition

The market features several prominent players, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare GmbH, Becton Dickinson and Company, Terumo Corporation, Beckman Coulter Inc., Mindray Medical International Limited, bioMérieux SA, Sysmex Corporation, Horiba Ltd., Nihon Kohden Corporation, Erba Mannheim, EKF Diagnostics Holding Plc., Nova Biomedical Corporation, Boule Diagnostics AB, Stanbio Laboratory LP, Drucker Diagnostics, A. Menarini Diagnostics Srl, Sensa Core, and Mikroscan Technologies Inc. These organizations compete by innovating product features, expanding distribution networks, and enhancing service capabilities.

Geographical Market Presence and Regional Leadership in Hematocrit Testing

In 2025, North America held the largest share of the hematocrit test devices market. However, the Asia-Pacific region is expected to exhibit the fastest growth rate during the forecast period. The market report covers regions such as Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a detailed global perspective on market trends and opportunities.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model